- Home
- EHGO vs PASG Comparison
EHGO vs PASG Comparison
Compare EHGO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHGO
- PASG
- Stock Information
- Founded
- EHGO 2015
- PASG 2017
- Country
- EHGO China
- PASG United States
- Employees
- EHGO N/A
- PASG N/A
- Industry
- EHGO
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- EHGO
- PASG Health Care
- Exchange
- EHGO NYSE
- PASG Nasdaq
- Market Cap
- EHGO 23.0M
- PASG 20.3M
- IPO Year
- EHGO 2024
- PASG 2020
- Fundamental
- Price
- EHGO $0.79
- PASG $5.74
- Analyst Decision
- EHGO
- PASG Strong Buy
- Analyst Count
- EHGO 0
- PASG 3
- Target Price
- EHGO N/A
- PASG $153.33
- AVG Volume (30 Days)
- EHGO 3.3M
- PASG 106.5K
- Earning Date
- EHGO 08-12-2025
- PASG 08-11-2025
- Dividend Yield
- EHGO N/A
- PASG N/A
- EPS Growth
- EHGO N/A
- PASG N/A
- EPS
- EHGO N/A
- PASG N/A
- Revenue
- EHGO $15,393,105.00
- PASG N/A
- Revenue This Year
- EHGO N/A
- PASG N/A
- Revenue Next Year
- EHGO N/A
- PASG N/A
- P/E Ratio
- EHGO N/A
- PASG N/A
- Revenue Growth
- EHGO N/A
- PASG N/A
- 52 Week Low
- EHGO $0.71
- PASG $5.12
- 52 Week High
- EHGO $5.50
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- EHGO N/A
- PASG 42.61
- Support Level
- EHGO N/A
- PASG $5.12
- Resistance Level
- EHGO N/A
- PASG $7.70
- Average True Range (ATR)
- EHGO 0.00
- PASG 0.75
- MACD
- EHGO 0.00
- PASG 0.01
- Stochastic Oscillator
- EHGO 0.00
- PASG 23.91
About EHGO ESHALLGO INC
Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.